about the author

Endpoints Contributor

help@endpts.com

author articles

For­get about greed, Pres­i­dent Trump: the vil­lain re­spon­si­ble for high drug prices is in­ef­fi­cien­cy

8 years ago

Ele­phants can't jump? IDEA's Mike Rea says some Big Phar­ma play­ers are crush­ing old be­liefs

8 years ago
R&D
Special

The Evolv­ing Over­all Sur­vival Ex­pec­ta­tions of Pa­tients with Re­lapsed or Re­frac­to­ry Mul­ti­ple Myelo­ma

8 years ago

On this Rare Dis­ease Day, let's all com­mit to help­ing rec­og­nize the life and work of biotech gi­ant Hen­ri A. Ter­meer

8 years ago
Biotech Voices

The win­ners and losers of the Swedish biotech in­dus­try IPO fren­zy

8 years ago

How as­set sup­ply and de­mand is shap­ing bio­phar­ma­ceu­ti­cal deal­mak­ing

8 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2017: In­flu­ences and Hot Spots

8 years ago

The myth of “lean­er and mean­er” phar­ma

9 years ago
R&D
Pharma

Three con­sid­er­a­tions for the phar­ma in­dus­try as Pres­i­dent Trump fo­cus­es on drug pric­ing

9 years ago
Biotech Voices
Pharma

CVS Leads Trend To­ward Less Ex­pen­sive Neu­trope­nia Treat­ments

9 years ago
First page Previous page 9101112
A service from the Financial Times